Explore our core research modules and analytical manufacturing programs engineered to accelerate discovery, regulatory clearance, and commercial-scale supply.
A macroeconomic and technical appraisal of the pharmaceutical and botanical supply chain evolution, driven by regulatory stringency, complex matrices, and time-to-market compression.
In modern life sciences, the global Contract Development and Manufacturing Organization (CDMO) paradigm has shifted from basic toll manufacturing (CMO) to comprehensive Original Design and Development Manufacturing (ODM/CDMO). Historically, pharmaceutical, nutraceutical, and dermaceutical brand sponsors managed distinct silos: discovery in academic or corporate wet labs, analytical validation with regional CROs, and toll-blending at third-party contract factories. This fragmented architecture caused intellectual property leaks, prolonged analytical tech-transfer delays, critical scale-up failures, and regulatory friction across FDA 21 CFR Part 211/111, EMA, and ICH Q7/Q11 guidelines.
This challenge is particularly severe in natural medicines, botanical drugs, and standardized phyto-bioactives. Unlike mono-molecular synthetic drugs, botanical matrices comprise multi-component phytocomplexes—alkaloids, flavonoids, polysaccharides, triterpenoid saponins, and volatile terpenes. These compounds exhibit pronounced seasonal fluctuations, origin-dependent chemotypes, and thermal vulnerabilities. A specialized ODM CDMO manufacturer bridges the chasm between raw botanical biomass and standardized, clinically substantiated commercial finished products.
Operating as MedGence Technical Co., Ltd. (Yineng Pharma) out of Changsha, China, our multidisciplinary research teams have directly served over 100 premier pharmaceutical groups, research universities, and Class-A tertiary TCM hospitals. Our scientific leadership has developed 22 innovative natural medicines, achieved 56 hospital preparation regulatory registrations, and characterized hundreds of thousands of research batches across our proprietary phytochemistry databases.
From primary molecular screening through preclinical models and industrial cGMP batch release, our integrated platform minimizes development risk across every milestone.
Systematic screening of complex plant secondary metabolites. We identify pharmacologically active target fractions using bioassay-guided fractionation and spectroscopic identification.
Multi-origin, seasonal, and botanical-part potency mapping. We quantify active ingredient density variations across harvest windows, microclimates, and regional cultivars.
Formulation of validated QC methods: HPLC, HPTLC, GC-MS, LC-MS/MS, and chromatographic fingerprinting to verify batch identity, purity, and active assay stability.
Systematic optimization of raw biomass pretreatment, extraction solvents, macro-porous resin purification, ceramic membrane separation, and crystallization parameters.
Overcoming organoleptic bitterness, active oxidation, and moisture sensitivity to formulate finished dosage forms with predictable in vivo release kinetics.
Comprehensive non-clinical safety profiling to determine safety windows, target organ toxicities, and clean toxicological dossiers for regulatory applications.
Cellular screening and molecular pathway assays validating biochemical mechanisms of action in metabolic syndrome, inflammation, oxidation, and skin health.
In vivo efficacy and pharmacokinetic verification across validated rodent disease models (STZ-induced diabetes, DSS colitis, hyperlipidemia, and immune modulation).
Design and execution of GCP-compliant human clinical trials. We manage pilot efficacy studies for dietary supplements and multi-center trials for new botanical drug submissions.
Transforming classical TCM formulas and multi-herb formulations into modern botanical medicines via modern phytopharmacology and compatibility science.
Industrial manufacturing of standardized botanical actives in multi-ton batch sizes under strict cGMP environments, ensuring supply chain security and IP protection.
Turnkey manufacturing of market-ready dosage forms with custom packaging, regulatory documentation, and continuous batch release testing.
How MedGence integrates modern analytical instrumentation, digital formulation engineering, and continuous processing to resolve botanical variability.
Employing multi-wavelength DAD-HPLC, Q-TOF-MS, and 2D-NMR fingerprinting coupled with multivariate statistical modeling (PCA, PLS-DA) to build multi-dimensional quality envelopes across varying raw harvests.
Replacing conventional static batch kettles with computerized continuous counter-current extractors (CCCE), increasing active fraction extraction yields by 18–35% while slashing thermal exposure and solvent consumption.
Overcoming the poor lipophilicity and gastrointestinal degradation of polyphenol and terpene actives via self-microemulsifying drug delivery systems (SMEDDS), phospholipid phytosomes, and cyclodextrin inclusions.
Incorporating Process Analytical Technology (PAT) using in-line Near-Infrared (NIR) sensors and Raman probes during commercial granulating, blending, and drying, guaranteeing strict CQA (Critical Quality Attributes) release.
Strategic ODM/CDMO execution customized for the North American, European Union, and Asia-Pacific regulatory jurisdictions.
Solutions engineered to meet FDA 21 CFR 111 cGMP compliance, Structure/Function claim substantiation packages, and NDI (New Dietary Ingredient) or GRAS (Generally Recognized as Safe) self-affirmation dossiers.
Compliance with the European Medicines Agency (EMA) HMPC herbal monographs, Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC), and EFSA Novel Food registration safety dossiers.
Formulation translation of verified hospital preparations, blue-hat health functional foods (SAMR), and Class 1.1/2.3 innovative traditional Chinese medicine drugs supported by clinical endpoints.
Our long-term contract research, analytical development, and pilot-to-commercial CDMO production directly support prestigious life-science organizations.
Exhaustive technical, contractual, and regulatory guidance for Chief Scientific Officers, heads of formulation, and pharmaceutical sourcing directors.
A standard CMO provides pure contract manufacturing based strictly on client-supplied tech packages and pre-established parameters. In contrast, an ODM (Original Design & Development) CDMO like MedGence manages the scientific continuum: de novo botanical active screening, agronomic potency evaluation, extraction optimization, complete ICH analytical validation, GLP safety toxicology, preclinical PD/PK, GCP clinical trials, and final cGMP commercialization. This eliminates data silos and scale-up discrepancies.
We resolve raw plant variance through a 3-tier chemometric control system: (1) Sourcing science: defining optimal harvest seasons, geo-authentic regional strains (Daodi), and precise anatomical plant parts; (2) Chemical fingerprinting: using multi-channel HPLC/GC-MS to construct holistic chromatographic profiles; and (3) Process standardization: tuning dynamic counter-current extraction parameters to establish reproducible active concentrations across every finished production run.
IP isolation is central to our entrusted contract model. We operate under stringent, legally enforceable international Non-Disclosure Agreements (NDAs). Client project data, chromatographic methods, molecular assays, and process recipes are isolated within dedicated project teams and encrypted data repositories. Clients retain full ownership of intellectual property generated during contract execution.
Our analytical suites utilize High-Performance Liquid Chromatography (HPLC-DAD/ELSD/FLD), High-Performance Thin-Layer Chromatography (HPTLC), Gas Chromatography (GC-FID/MS), Triple-Quadrupole LC-MS/MS, and Inductively Coupled Plasma Mass Spectrometry (ICP-MS). We establish validated assay methods for target actives, chromatographic fingerprint identification, residual solvent testing, heavy metal limits, pesticide residue screening, and mycotoxin quantification.
Yes. Our pilot facility directly bridges laboratory glassware with commercial reactors. We utilize standardized scale-up equations (evaluating Reynolds numbers, heat transfer coefficients, and mass transfer dynamics) across our pilot extraction, micro-filtration, concentration, and spray-drying towers. This guarantees that parameters validated in research translate seamlessly into 10-ton commercial batches.
For active pharmaceutical ingredients (APIs) and botanical extracts, we supply concentrated liquids, spray-dried powders, standardized pastes, and supercritical volatile oils. For finished commercial products, our facilities manufacture oral liquids, hard gelatin/vegetarian capsules, softgels, enteric-coated tablets, sublingual powders, and dispersible effervescent granules.
Yes. We conduct complete preclinical toxicology suites (acute LD50, 90-day sub-chronic repeated dose, Ames, in vitro chromosomal aberration) and efficacy trials in animal models. Furthermore, we design and coordinate Phase I human pharmacokinetics, small-group human trials for dietary supplement substantiation, and Phase II–IV multi-center GCP clinical trials for botanical New Drug Applications (NDAs).
Our research institute has modernized 83 classic TCM formulas and registered 56 official hospital preparations. We conduct herb-herb interaction profiling, identify active synergists, eliminate heavy metals and toxic impurities, develop chromatographic fingerprint standards, and reformulate bulky decoctions into elegant, concentrated modern oral dosage forms.
Select specialized research modules and commercial CDMO manufacturing services to fulfill your pipeline requirements.
Share your target indication, bioactive marker compound, required batch yield, or regulatory destination. Our scientific team will provide a comprehensive project brief encompassing feasibility, analytical methodology, study timeline, and scale-up economics.
